Clonal evolution of colorectal cancer in IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 14, Issue 4, 2017, Pages 218-229

  Choi, Chang Ho R ^a,b   Bakir, Ibrahim Al ^a,b   Hart, Ailsa L ^b   Graham, Trevor A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER STEM CELL; CLONAL EVOLUTION; COLON BIOPSY; COLORECTAL CANCER; DYSPLASIA; EPIGENETICS; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM; MICROENVIRONMENT; MUTATIONAL ANALYSIS; NONHUMAN; PROCESS OPTIMIZATION; REVIEW; RISK ASSESSMENT; SCREENING TEST; SOMATIC MUTATION; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; COMPLICATION; GENETIC PREDISPOSITION; GENETICS;

BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 85011850775     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2017.1     Document Type: Review

References (134)

1. Kaser, A., Zeissig, S., Blumberg, R. S. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621 (2010).
2. Kaplan, G. G. The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12, 720-727 (2015).
3. Adami, H., et al. The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut 65, 889-893 (2016).
4. Eaden, J. A., Abrams, K. R., Mayberry, J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535 (2001).
5. Castanõ-Milla, C., Chaparro, M., Gisbert, J. P. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment. Pharmacol. Ther. 39, 645-659 (2014).
6. Jess, T., Rungoe, C., Peyrin-Biroulet, L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 10, 639-645 (2012).
7. Rutter, M. D., et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130, 1030-1038 (2006).
8. Baars, J. E., et al. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J. Gastroenterol. 47, 1308-1322 (2012).
9. Bansal, P., Sonnenberg, A. Risk factors of colorectal cancer in inflammatory bowel disease. Am. J. Gastroenterol. 91, 44-48 (1996).
10. Mattar, M. C., Lough, D., Pishvaian, M. J., Charabaty, A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest. Cancer Res. 4, 53-61 (2011).
11. Choi, C.-H. R., et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am. J. Gastroenterol. 110, 1022-1034 (2015).
12. Lam, A. K.-Y., Chan, S. S.-Y., Leung, M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World J. Gastroenterol. 20, 6815-6820 (2014).
13. Itzkowitz, S. H., Yio, X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G7-G17 (2004).
14. Mooiweer, E., et al. Incidence of interval colorectal cancer among inflammatory bowel disease patients undergoing regular colonoscopic surveillance. Clin. Gastroenterol. Hepatol. 13, 1656-1661 (2015).
15. Harpaz, N., Polydorides, A. Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, pathogenesis. Arch. Pathol. Lab. Med. 134, 876-895 (2010).
16. van Schaik, F. D. M., et al. Endoscopic and pathological aspects of colitis-associated dysplasia. Nat. Rev. Gastroenterol. Hepatol. 6, 671-678 (2009).
17. DeRoche, T. C., Xiao, S.-Y., Liu, X. Histological evaluation in ulcerative colitis. Gastroenterol. Rep. 2, 178-192 (2014).
18. Mooiweer, E., et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am. J. Gastroenterol. 110, 1014-1021 (2015).
19. Zisman, T. L., et al. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm. Bowel Dis. 18, 2240-2246 (2012).
20. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
21. Merlo, L. M. F., Pepper, J. W., Reid, B. J., Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924-935 (2006).
22. Greaves, M., Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
23. Sansom, O. J., et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, migration. Genes Dev. 18, 1385-1390 (2004).
24. Leedham, S. J., et al. Clonality, founder mutations, field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 136, 542-550. e6 (2009).
25. Galandiuk, S., et al. Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis. Gastroenterology 142, 855-864. e8 (2012).
26. Holzmann, K., et al. Comparative analysis of histology, DNA content, 53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int. J. Cancer 76, 1-6 (1998).
27. Chaubert, P., Benhattar, J., Saraga, E., Costa, J. K-Ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am. J. Pathol. 144, 767-775 (1994).
28. Slaughter, D. P., Southwick, H. W., Smejkal, W. 'Field cancerization' in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 6, 963-968 (1953).
29. Braakhuis, B. J. M., Tabor, M. P., Kummer, J. A., Leemans, C. R., Brakenhoff, R. H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63, 1727-1730 (2003).
30. Zhu, D., et al. K-Ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res. 57, 2485-2492 (1997).
31. Hsieh, J. C. F., Van Den Berg, D., Kang, H., Hsieh, C.-L. L., Lieber, M. R. Large chromosome deletions, duplications, gene conversion events accumulate with age in normal human colon crypts. Aging Cell 12, 269-279 (2013).
32. Nosho, K., et al. A prospective cohort study shows unique epigenetic, genetic, prognostic features of synchronous colorectal cancers. Gastroenterology 137, 1609-1620. e3 (2009).
33. Cooper, H. S., Murthy, S., Kido, K., Yoshitake, H., Flanigan, A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 21, 757-768 (2000).
34. Clapper, M. L., et al. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 14, 1341-1347 (2008).
35. Ekbom, A., Helmick, C., Zack, M., Adami, H. O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 323, 1228-1233 (1990).
36. Risques, R. A., et al. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, inflammation. Cancer Res. 71, 1669-1679 (2011).
37. Grivennikov, S. I. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin. Immunopathol. 35, 229-244 (2013).
38. Ghosh, S., Hayden, M. S. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 8, 837-848 (2008).
39. Atreya, I., Atreya, R., Neurath, M. F. NF-B in inflammatory bowel disease. J. Intern. Med. 263, 591-596 (2008).
40. Greten, F. R., et al. IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (2004).
41. Brown, J. B., et al. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 138, 595-605. e3 (2010).
42. Lee, G., et al. Phosphoinositide 3-kinase signaling mediates B-catenin activation in intestinal epithelial stem and progenitor cells in colitis. 139, 869-881 (2010).
43. Schwitalla, S., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38 (2013).
44. Mudter, J., et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am. J. Gastroenterol. 100, 64-72 (2005).
45. Bollrath, J., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102 (2009).
46. Marusyk, A., Tabassum, D. P., Altrock, P. M., Almendro, V., Michor, F. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514, 54-58 (2014).
47. Michael-Robinson, J. M., et al. Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer. J. Pathol. 208, 381-387 (2006).
48. Arthur, J. C., et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 5, 4724 (2014).
49. Arthur, J. C., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123 (2012).
50. Schwerbrock, N. M. J., et al. Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria. Inflamm. Bowel Dis. 10, 811-823 (2004).
51. Prorok-Hamon, M., et al. Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut 63, 761-770 (2014).
52. Kostic, A. D., Xavier, R. J., Gevers, D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146, 1489-1499 (2014).
53. McCoy, A. N., et al. Fusobacterium is associated with colorectal adenomas. PLoS ONE 8, e53653 (2013).
54. Strauss, J., et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis. 17, 1971-1978 (2011).
55. Rhodes, J. M., Campbell, B. J., Yu, L.-G. Lectin-epithelial interactions in the human colon. Biochem. Soc. Trans. 36, 1482-1486 (2008).
56. Itzkowitz, S. H., et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Gastroenterology 110, 694-704 (1996).
57. Robles, A. I., et al. Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology 150, 931-943 (2016).
58. Yaeger, R., et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology 151, 278-287. e6 (2016).
59. Seegert, D., et al. Increased expression of IL-16 in inflammatory bowel disease. Gut 48, 326-332 (2001).
60. Wang, P., et al. IL-16 induces intestinal inflammation via PepT1 upregulation in a pufferfish model: new insights into the molecular mechanism of inflammatory bowel disease. J. Immunol. 191, 1413-1427 (2013).
61. Alexandrov, L. B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
62. Alexandrov, L. B., et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402-1407 (2015).
63. Issa, J. P., Ahuja, N., Toyota, M., Bronner, M. P., Brentnall, T. A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61, 3573-3577 (2001).
64. Brentnall, T., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107, 369-378 (1994).
65. Kato, S., et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA 100, 8424-8429 (2003).
66. Chang, W. C. I., et al. Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Carcinogenesis 28, 2375-2381 (2007).
67. Lamlum, H., et al. APC mutations are sufficient for the growth of early colorectal adenomas. Proc. Natl Acad. Sci. USA 97, 2225-2228 (2000).
68. Dow, L. E., et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161, 1539-1552 (2015).
69. Shenoy, A. K., et al. Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors. Cancer Res. 72, 5091-5100 (2012).
70. Miyoshi, H., et al. Wnt5a potentiates TGF-signaling to promote colonic crypt regeneration after tissue injury. Science 338, 108-113 (2012).
71. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
72. Schulmann, K., et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 129, 74-85 (2005).
73. van Dieren, J. M., et al. Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. Diagn. Mol. Pathol. 15, 216-222 (2006).
74. Vermeulen, L., Snippert, H. J. Stem cell dynamics in homeostasis and cancer of the intestine. Nat. Rev. Cancer 14, 468-480 (2014).
75. Barker, N., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (2007).
76. Ritsma, L., et al. Intestinal crypt homeostasis revealed at single-stem-cell level by in vivo live imaging. Nature 507, 362-365 (2014).
77. Tian, H., et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478, 255-259 (2011).
78. Barker, N., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611 (2009).
79. Humphries, A., Wright, N. A. Colonic crypt organization and tumorigenesis. Nat. Rev. Cancer 8, 415-424 (2008).
80. Snippert, H. J., et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134-144 (2010).
81. Vermeulen, L., et al. Defining stem cell dynamics in models of intestinal tumor initiation. Science 342, 995-998 (2013).
82. Biswas, S., et al. Microenvironmental control of stem cell fate in intestinal homeostasis and disease. J. Pathol. 237, 135-145 (2015).
83. Francoeur, C., et al. Degeneration of the pericryptal myofibroblast sheath by proinflammatory cytokines in inflammatory bowel diseases. Gastroenterology 136, 268-277. e3 (2009).
84. Yao, T., Talbot, I. C. The demonstration of pericryptal fibroblasts in background mucosa and dysplasia complicating ulcerative colitis. Histopathology 28, 325-331 (1996).
85. Greaves, L. C., et al. Mitochondrial DNA mutations are established in human colonic stem cells, mutated clones expand by crypt fission. Proc. Natl Acad. Sci. USA 103, 714-719 (2006).
86. Langlands, A. J., et al. Paneth cell-rich regions separated by a cluster of Lgr5+ cells initiate crypt fission in the intestinal stem cell niche. PLoS Biol. 14, e1002491 (2016).
87. Loeffler, M., Bratke, T., Paulus, U., Li, Y. Q., Potten, C. S. Clonality and life cycles of intestinal crypts explained by a state dependent stochastic model of epithelial stem cell organization. J. Theor. Biol. 186, 41-54 (1997).
88. Cheng, H., Bjerknes, M., Amar, J., Gardiner, G. Crypt production in normal and diseased human colonic epithelium. Anat. Rec. 216, 44-48 (1986).
89. Snippert, H. J., Schepers, A. G., Van Es, J. H., Simons, B. D., Clevers, H. Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion. EMBO Rep. 15, 62-69 (2014).
90. Pruitt, S. C., Freeland, A., Kudla, A. Cell cycle heterogeneity in the small intestinal crypt and maintenance of genome integrity. Stem Cells 28, 1250-1259 (2010).
91. Scher, M., Werner, S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 9, 628-638 (2008).
92. Lai, L. A., et al. Pan-colonic field defects are detected by CGH in the colons of UC patients with dysplasia/cancer. Cancer Lett. 320, 180-188 (2012).
93. Yui, S., et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell. Nat. Med. 18, 618-623 (2012).
94. Nystul, T., Spradling, A. An epithelial niche in the Drosophila ovary undergoes long-range stem cell replacement. Cell Stem Cell 1, 277-285 (2007).
95. Thorsteinsdottir, S., Gudjonsson, T., Nielsen, O. H., Vainer, B., Seidelin, J. B. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat. Rev. Gastroenterol. Hepatol. 8, 395-404 (2011).
96. Rubin, C. E., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103, 1611-1620 (1992).
97. Lashner, B. A., Shapiro, B. D., Husain, A., Goldblum, J. R. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am. J. Gastroenterol. 94, 456-462 (1999).
98. Gerrits, M. M., et al. Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. Cell. Oncol. (Dordr. ) 34, 107-117 (2011).
99. Marusyk, A., Almendro, V., Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer Nat. Rev. Cancer 12, 323-334 (2012).
100. Solaymani-Dodaran, M., Logan, R. F. A., West, J., Card, T., Coupland, C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53, 1070-1074 (2004).
101. Weaver, J. M. J., et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843 (2014).
102. Ein-Dor, L., Zuk, O., Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA 103, 5923-5928 (2006).
103. Papaemmanuil, E., et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209-2221 (2016).
104. Masel, J., Trotter, M. V. Robustness and evolvability. Trends Genet. 26, 406-414 (2010).
105. Maley, C. C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006).
106. Martinez, P., et al. A dynamic clonal equilibrium predicts cancer risk in Barrett's oesophagus. Nat. Commun. 7, 12158 (2016).
107. Salk, J. J., et al. Clonal expansions in ulcerative colitis identify patients with neoplasia. Proc. Natl Acad. Sci. USA 106, 20871-20876 (2009).
108. Li, X., et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev. Res. (Phila. ) 7, 114-127 (2014).
109. Itzkowitz, S. H., et al. Sialosyl-Tn antigen: initial report of a new marker of malignant progression in long-standing ulcerative colitis. Gastroenterology 109, 490-497 (1995).
110. Lofberg, R., Brostrom, O., Karlen, P., Ost, A., Tribukait, B. DNA aneuploidy in ulcerative-colitis-reproducibility, topographic distribution, relation to dysplasia. Gastroenterology 102, 1149-1154 (1992).
111. Burmer, G. C., et al. Neoplastic progression in ulcerative colitis: histology, DNA content, loss of a p53 allele. Gastroenterology 103, 1602-1610 (1992).
112. Greaves, L. C., et al. Clonal expansion of early to mid-life mitochondrial DNA point mutations drives mitochondrial dysfunction during human ageing. PLoS Genet. 10, e1004620 (2014).
113. Shergill, A. K., et al. The role of endoscopy in inflammatory bowel disease. Gastrointest. Endosc. 81, 1101-1121. e13 (2015).
114. Rabinovitch, P. S., et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res. 59, 5148-5153 (1999).
115. Torres, J., de Chambrun, G. P., Itzkowitz, S., Sachar, D. B., Colombel, J.-F. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment. Pharmacol. Ther. 34, 497-508 (2011).
116. Laine, L., et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology 148, 639-651. e28 (2015).
117. Algra, A. M., et al. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518-527 (2012).
118. Asano, T. K., McLeod, R. S. Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst. Rev. 2, CD004079 (2004).
119. Kostadinov, R. L., et al. NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet. 9, e1003553 (2013).
120. Zhao, L.-N., et al. 5-aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS ONE 9, e94208 (2014).
121. Gupta, R. B., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133, 1099-1105 (2007).
122. Zallot, C., Peyrin-Biroulet, L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr. Gastroenterol. Rep. 15, 315 (2013).
123. Levine, D. S., et al. Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology 101, 1198-1210 (1991).
124. Brentnall, T. A., et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 56, 1237-1240 (1996).
125. Willenbucher, R., Zelman, S., Ferrell, L., Moore, D., Waldman, F. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 113, 791-801 (1997).
126. Willenbucher, R. F., et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol. 154, 1825-1830 (1999).
127. O'Sullivan, J. N., et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 32, 280-284 (2002).
128. Chen, R., et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am. J. Pathol. 162, 665-672 (2003).
129. Yoshida, T., Mikami, T., Mitomi, H., Okayasu, I. Diverse p53 alterations in ulcerative colitis-associated low-grade dysplasia: full-length gene sequencing in microdissected single crypts. J. Pathol. 199, 166-175 (2003).
130. Sjvist, U., et al. Colorectal cancer in colonic Crohn's disease-high frequency of DNA-aneuploidy. Anticancer Res. 25, 4393-4397 (2005).
131. Garrity-Park, M. M., Loftus, E. V. J., Sandborn, W. J., Bryant, S. C., Smyrk, T. C. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am. J. Gastroenterol. 105, 1610-1619 (2010).
132. Serlund, S., et al. Colitis-associated DNA aneuploidy and dysplasia in Crohn's disease and risk of colorectal cancer. Inflamm. Bowel Dis. 17, 1101-1107 (2011).
133. Salk, J. J., et al. Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis. Inflamm. Bowel Dis. 19, 2593-2602 (2013).
134. Choi, W.-T., et al. Outcome of 'indefinite for dysplasia' in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer. Hum. Pathol. 46, 939-947 (2015).